Effects of non-surgical periodontal therapy on the glomerular filtration rate of the kidney: an exploratory trial.

OBJECTIVE: To determine whether non-surgical periodontal treatment (PT) would exert, in subjects with generalized chronic periodontitis (GCP), some beneficial effect on renal function as indicated by surrogate measures of the glomerular filtration rate (GFR). MATERIAL AND METHODS: Twenty GCP systemically healthy subjects were treated with PT. Serum samples were collected at baseline and 1 day, 7, 30, 90 and 180 days after treatment. GFR was evaluated using cystatin C, a serum marker and modification of diet in renal disease (MDRD), an equation involving creatinine, urea and albumin. Serum markers of systemic inflammation such as C-reactive protein (CRP), D-dimer, serum amyloid A (SAA) and fibrinogen were also assessed. RESULTS: The cystatin C level decreased significantly from baseline to the end of the trial (p<0.01). Conversely, MDRD did not vary. A significant inflammatory reaction was produced by PT in the short term. Greater increases were noted for CRP and SAA within 24 h (p<0.001 versus baseline), while D-dimer (p<0.05) and fibrinogen (p<0.01) showed mild variations. The values of inflammatory markers were normalized after 30 days. CONCLUSIONS: GFR, as assessed by cystatin C levels, may be positively affected by PT. Because of the exploratory nature of this trial, further research is needed to investigate this preliminary finding.

Lack of short-term adjunctive effect of systemic neridronate in non-surgical periodontal therapy of advanced generalized chronic periodontitis: an open label-randomized clinical trial.

AIM: To determine if the adjunctive use of intra-muscular neridronate (NE) during non-surgical periodontal treatment (PT) provides, in patients with generalized chronic periodontitis (GCP), adjunctive benefits as compared with PT alone 3 months after the completion of a 3-month NE therapy. MATERIAL AND METHODS: Sixty GCP healthy patients were randomly assigned to control (CG) or test group (TG). CG patients received PT only. Thirty subjects in TG also received adjunctive NE (12.5 mg in an i.m. injection/week for 3 months). Clinical parameters were evaluated at baseline, at the end of NE treatment (3 months after PT) and 3 months after the completion of NE treatment (6 months after the beginning of PT). RESULTS: Groups were balanced at baseline and all clinical parameters showed improvement between baseline and follow-ups. At 6 months improvements from baseline at sites with deep pocket depth (>or=7 mm) were 3.2 mm [95% confidence interval (CI): 2.7-3.9] in CG and 3.0 mm (95% CI: 2.3-3.8) in TG with a non-significant difference of 0.2 mm (95% CI: -1.0-0.5; ANCOVA; p=0.549) between groups. Secondary outcomes did not show significant differences between groups. No major adverse events were reported. CONCLUSIONS: The adjunctive use of NE during PT did not result in additional short-term improvements in periodontal conditions of GCP patients when compared with PT.

The effects of systemic alendronate with or without intraalveolar collagen sponges on postextractive bone resorption: a single masked randomized clinical trial.

Alendronate is a bisphosphonate frequently used to reduce bone resorption. It has been used for osteoporosis, Paget's disease, and also as adjunctive therapy for periodontal disease. The aim of this study was to evaluate the effect of systemic alendronate with or without endoalveolar collagen sponge on vertical bone resorption after lower wisdom tooth extraction. Forty patients referred for wisdom tooth impaction were selected. Before surgery, patients were randomly assigned to receive one of the following pharmacologic treatments: no medication (group 1), postextractive endoalveolar collagen sponge (group 2), systemic alendronate for 4 months starting the day of surgery (group 3), and group 2 + group 3 (group 4). Standardized orthopantomographic evaluation was obtained during recruitment (T1), immediately after surgery (T2), and 4 months (T3) to evaluate crestal and alveolar socket changes. Results indicate that at T2, crest and socket level did not show significant differences between the four groups. At T3, test sites treated showed less bone resorption compared with controls. In particular, higher vertical bone height levels and a faster intraalveolar healing were achieved in groups 3 and 4. Systemically given alendronate may be used successfully to reduce vertical bone resorption after wisdom tooth extraction.

A systematic review of the effectiveness of bone collectors.

PURPOSE: Bone collectors are used to harvest bone debris for grafting procedures during implant surgery. The particulate bone debris gathered through filtration has been frequently used in minor regenerative surgical procedures. Nevertheless, the biological potency of such grafts is still unclear. The objective of this study was to systematically review the use of bone collectors in implant dentistry, focusing on the quantity, quality, and bacterial contamination of the bone collected. MATERIALS AND METHODS: Following the production of a detailed protocol, screening and quality assessment of the literature were conducted in duplicate and independently. The outcome measures that were assessed were: (1) quantity of collected debris, (2) quality of the collected bone debris, and (3) bacterial contamination. RESULTS: There is a limited amount of information on the nature of bone obtained through collectors. Eleven studies satisfied the inclusion criteria. Bone collectors are able to retain a small amount of bone for minor surgical procedures. The presence of vital bone cells has not been demonstrated routinely, while consistent bacterial contamination has been observed. DISCUSSION: Bone collected through bone filters appears to be sufficient for small regenerative procedures. Clinicians should bear in mind that presence of bacterial pathogens is always shown with the use of bone collectors. Presurgical chlorhexidine oral rinsing and a strict aspiration protocol must be used to minimize the bacterial contamination of the debris collected. CONCLUSIONS: Although bone collectors are capable of amassing small amounts of bone, the vitality of this bone could not be consistently demonstrated and the collected debris was always contaminated by bacteria. Therefore, the bone debris amassed in bone collectors is not an ideal grafting material and should be utilized with caution.

An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw.

BACKGROUND: Bisphosphonate (BP)-related osteonecrosis of the jaw (ONJ) is an unpredictable, debilitating adverse effect. Recently, genetic polymorphisms have arisen as promising tools to identify patients with a higher risk of drug-related adverse events. AIM: We aimed to examine the association between the aromatase polymorphism g.132810C>T, and the estrogen receptor polymorphisms g.156705T>C and g.156751A>G, and the risk of BP-related ONJ. METHODS: Eighty-three subjects were included in the study. A clinical and radiological examination was conducted on oncologic subjects treated with zoledronic acid. Subjects with histologically confirmed ONJ were included in the test group (n = 30) whereas subjects with good oral health were included in control group (n = 53). Aromatase and estrogen receptor polymorphisms from blood samples were analyzed. RESULTS: The aromatase g.132810C>T polymorphism displayed an over-representation of the TT genotype in the test group (36.67 vs 16.98%; p < 0.05). There was no significant difference in either estrogen receptor polymorphism genotype frequency between the test and control groups. CONCLUSION: Our data suggest a role for the g.132810C>T polymorphism in predicting ONJ risk. These results can pave the way to the personalization of BP therapy, based on individual genotype.

Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonates therapy.

Bisphosphonates (BPs) are used to inhibit bone resorption. Recently, they have been used in cancer patients to prevent bone loss due to bone metastasis. Fourteen consecutive patients, undergoing BPs monthly IV infusion due to neoplastic bone diseases, were diagnosed with osteonecrosis of the jaws. None of the patients had been previously undergoing radiotherapy of the head and neck region. Eight patients showed maxillary involvement, and nine patients had had a recent tooth extraction in the osteonecrosis areas. Biopsies and surgical debridment were performed. Histologically, none of the patients showed signs of bone metastasis. As high-dosage long-term BP therapy appears to be associated with osteonecrosis of the jaws, dental practitioners should exercise caution in the treatment of such patients.